Global Small Scale Bioreactors Market, by Product Type [Reusable Bioreactors ( Stainless Steel Bioreactors, Glass Bioreactors) Single-use Bioreactor] By Capacity (5 ML-100 ML,100 ML-250ML, 250ML-500ML, 500ML-1L, 1L-3L, 3L-5L), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Research Organizations), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,233.5 million in 2021 and is expected to exhibit a CAGR of 10.6% during the forecast period (2021-2028).
Increasing marketing activities for products by the market players is expected to drive the growth of the global small scale bioreactors market over the forecast period. For instance, on April 1, 2021, Getinge announced to become the supplier of Applikon bioreactors in France, Sweden, and Germany. Getinge is a global medical technology company which had acquired Applikon, a manufacturer of bioreactors, on January 1, 2020.
Key players are focused on research and development activities on small scale bioreactors, which is expected to drive the growth of the global small scale bioreactors market over the forecast period. For instance, on April 20, 2018, Sartorius Stedim Biotech which is pharmaceutical industry’s leading worldwide partner introduced Mini Microcarrier Bioreactor for Culturing Adherent Cells. This device will be cost effective and vaccine development will possible with cell cultures by using scalable processing. The capacity of this device is 100ML- 250ML.This mini vessel is tested by bioprocess experts at Aston University and university college of London where it came about as the gadget is empowered for development to intersection of vero cells on cytodex micro carrier’s surface.
Global Small Scale Bioreactors Market- Impact of Coronavirus (COVID – 19) Pandemic
The coronavirus disease (COVID-19) pandemic is expected to drive growth of the global small scale bioreactors market over the forecast period. COVID-19 is the recent pandemic outbreak which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases and deaths continued to decrease, with nearly 258 million cases of COVID-19 were reported globally and with just under 5,174,646 deaths till November 24, 2021.
Increasing involvement of market players in research and developments is expected to increase the growth of the global small scale bioreactors market over the forecast period. For instance, according to the annual report 2020 of Getinge AB, a global medical technology company, biopharmaceutical has grown rapidly in the last two years 2019-20, owing to its ability to create customized drugs that target very specific health conditions. This trend has become even more pronounced in the collective search for a potent COVID-19 vaccine in 2020. Getinge introduced high performance R & D bioreactor structures, expanding the production of bioreactors structures without compromising the integrity of the bioreactor, and reducing the risk of infection at final stage of production .
Browse 31 Market Data Tables and 46 Figures spread through 196 Pages and in-depth TOC on Global Small Scale Bioreactors Market, by Product Type [Reusable Bioreactors (Stainless Steel Bioreactors, Glass Bioreactors), Single-use Bioreactor], By Capacity (5 ML-100ML, 100ML-250ML, 250ML-500ML, 500ML-1L, 1L-3L, 3L-5L), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, Research Organizations ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the global small scale bioreactors market, click the link below:
https://www.coherentmarketinsights.com/market-insight/small-scale-bioreactors-market-4828
Increasing prevalence of diseases indicates the need of vaccine production which is expected to drive the growth of the global small scale bioreactors market over the forecast period. For instance, Medigene is working on the development of innovative immunotherapies such as T cell activity against solid cancers such as receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines to treat cancer .The first product candidates are in clinical development.
Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.
Key Takeaways of the Small Scale Bioreactors Market:
- The global small scale bioreactors market is expected to exhibit a CAGR of 10.6% over the forecast period (2021-2028), owing to growth in potential markets, especially in Europe, while North America region accounted for the major market share for year 2020.
- Key players operating in the market are focusing on investing in bioreactors and manufacturing facilities containing bioreactors for the development of drugs, vaccines, and cell culture based products, which is expected to drive the growth of small scale bioreactors. For instance, in July 2021, Cytiva and Pall Corporation, both Danaher Corporation subsidiaries, announced plans to invest US$ 1.5 billion to expand manufacturing capacity for their life science customers across 13 sites globally. The companies will invest in chromatography resins, cell culture media, and single-use bioreactor technologies.
- Some of the major players operating in the global small scale bioreactors market include Merck KGaA , Danaher Corporation, Getinge AB, Sartorius AG ,Thermo Fisher Scientific Inc., Lonza Group, Eppendorf AG, Miltenyi Biotec, Solaris Biotechnology Srl, Infors AG,Biosan, MicroDigital Co. Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf Kühner AG, Ori Biotech, Aglaris and AdvaBio.
